MARKET

ADAP

ADAP

Adaptimmune Therapeutics Plc
NASDAQ
0.4461
-0.0291
-6.12%
After Hours: 0.4500 +0.0039 +0.87% 19:35 11/28 EST
OPEN
0.4693
PREV CLOSE
0.4752
HIGH
0.4797
LOW
0.4205
VOLUME
363.32K
TURNOVER
0
52 WEEK HIGH
2.380
52 WEEK LOW
0.4200
MARKET CAP
101.32M
P/E (TTM)
-0.9117
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ADAP last week (1120-1124)?
Weekly Report · 2d ago
Weekly Report: what happened at ADAP last week (1113-1117)?
Weekly Report · 11/20 09:31
Adaptimmune Therapeutics Plc: Current report
Press release · 11/14 14:19
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NASDAQ · 11/13 14:35
Weekly Report: what happened at ADAP last week (1106-1110)?
Weekly Report · 11/13 09:29
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)
TipRanks · 11/10 11:40
Analysts Have Conflicting Sentiments on These Healthcare Companies: ADMA Biologics (ADMA), Adaptimmune Therapeutics (ADAP) and Bioxcel Therapeutics (BTAI)
TipRanks · 11/09 19:38
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Adaptimmune therapeutics plc (nasdaq:adap) analysts have upgraded their forecasts for next year's revenue and earnings per share. The consensus is now more bullish on the company's business prospects. The share price is up 4.2% over the past 7 days after the upgrade. However, adaptimmune's decline is expected to accelerate, with revenues forecast to fall 21% in 2024.
Simply Wall St · 11/09 12:29
More
About ADAP
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Webull offers Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ: ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.